Medicaid now incentivizes cancer education for sickle cell patients
H.R. 124 — Byron Nash Renal Medullary Carcinoma Awareness Act of 2023 · Filed by Al Green (D-TX) · Introduced Jan 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicaid law to require states to provide education about renal medullary carcinoma (a rare kidney cancer) to Medicaid beneficiaries who have sickle cell disease, treating it the same way Medicaid currently treats education about stroke risk. The bill creates a financial incentive for states to deliver this education by including it in Medicaid's quality-measurement and payment framework.
Why we flagged it
The bill's operative mechanism is a straightforward amendment to Medicaid's quality-incentive framework, adding renal medullary carcinoma education to the list of health topics states are paid to educate beneficiaries about. It is a targeted public-health measure, not a commemorative or vanity provision despite the personal name in the title.
What the text implies
- The bill does not specify funding or appropriations; the incentive operates within existing Medicaid payment structures, so implementation depends on CMS rulemaking and state participation rates.
- Renal medullary carcinoma is extremely rare and disproportionately affects Black Americans with sickle cell disease; this bill targets a health disparity but does not address broader barriers to cancer screening or treatment access.
The full analysis lists 3 implications of this text.
Who it affects
Medicaid beneficiaries with sickle cell disease gain access to education about a cancer risk specific to their condition, enabling earlier detection and informed health decisions. States are incentivized to deliver this education through existing Medicaid payment mechanisms, at no direct cost to patients.